Inactive Instrument

Cosmo Pharmaceuticals S.p.A Stock Swiss Exchange

Equities

IT0004167463

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for Cosmo Pharmaceuticals S.p.A

Financials

Sales 2024 * 264M 282M 254M Sales 2025 * 242M 259M 233M Capitalization 1.17B 1.25B 1.13B
Net income 2024 * 124M 133M 119M Net income 2025 * 76M 81.38M 73.12M EV / Sales 2024 * 3.99 x
Net cash position 2024 * 120M 128M 115M Net cash position 2025 * 210M 225M 202M EV / Sales 2025 * 3.97 x
P/E ratio 2024 *
9.53 x
P/E ratio 2025 *
12.8 x
Employees -
Yield 2024 *
2.88%
Yield 2025 *
1.05%
Free-Float 44.36%
More Fundamentals * Assessed data

Latest transcript on Cosmo Pharmaceuticals S.p.A

Managers TitleAgeSince
Director of Finance/CFO 52 16-05-31
Chairman 61 05-12-31
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Founder 69 96-12-31
Director/Board Member 69 12-03-31
Chairman 61 05-12-31
More insiders
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
More about the company